New diagnostic test can detect chlamydia trachomatis in less than 20 minutes

December 12, 2013, Elsevier

Researchers have developed a new assay for rapid and sensitive detection of Chlamydia trachomatis, the most common sexually transmitted infection (STI) in humans. This procedure takes less than 20 minutes and can be easily performed at the point of care (POC) during the patient's visit, reports The Journal of Molecular Diagnostics.

C. trachomatis affects 5% to 10% of the population and is particularly common in young adults under 25 years. It is a major public health concern due to its prevalence and potential severe long-term consequences. One of the main reasons it is so prevalent is that in the majority of cases (75% of women and 50% of men) there are minimal to no symptoms, and it therefore often goes undiagnosed. Infection is associated with non-gonococcal urethritis in men and several inflammatory reproductive tract syndromes in women such as inflammation of the uterine cervix and pelvic inflammatory disease. Untreated, the infection increases the risk of ectopic pregnancy and is one of the leading causes of female infertility worldwide.

The assay uses recombinase polymerase amplification (RPA), a nucleic acid amplification technique (NAAT), to detect C. trachomatis directly from urine samples. Because the assay's novel approach does not require the purification of total DNA from the urine sample, the need for specialized equipment is eliminated. The procedure is significantly less laborious, less time-consuming, and consequently less expensive. It is relatively simple to perform and could therefore be applied in numerous POC settings.

"The assay enables highly specific C. trachomatis detection with sensitivity levels significantly improved compared to currently available C. trachomatis POC assays," says Ülo Langel, PhD, Professor of Molecular Biotechnology, University of Tartu, Estonia, and Professor of Neurochemistry, Stockholm University, Sweden.

Existing (PCR)-based techniques for testing C. trachomatis are widely applied but are only suitable for use in hospitals with trained staff and expensive machinery. Studies have shown that up to 50% of patients never return to get the diagnostic result or required treatment.

Although several rapid-diagnosis POC tests have already been developed, none offer a comparable sensitivity to hospital-based techniques. Recent independent studies have shown that currently available POC tests have a sensitivity of just 10% to 40%. Initial analysis of the new assay's performance indicated a specificity of 100% and a sensitivity of 83%, evidence of its potential reliability.

"The alarmingly poor performance of the available POC tests for C. trachomatis has limited their wider use, and there is a clear requirement for more sensitive and cost-effective diagnostic platforms. Hence, the need for an applicable on-site test that offers reasonably sensitive detection," concludes Prof. Langel.

Technical details of the study

Recombinase polymerase amplification (RPA) is a nucleic acid amplification technique (NAAT) – a laboratory technique that involves the in vitro synthesis of many copies of DNA or RNA from one original template. These techniques have revolutionized diagnostic technology. Current technologies that allow the detection of amplification in real time are fast becoming diagnostic industry standards.

C. trachomatis cells contain plasmids (small DNA molecules that are separate from chromosomal DNA) that have a number of coding sequences. For identification and amplification by RPA, researchers selected a gene fragment within a gene (CDS2) that was conserved across sexually transmitted C. trachomatis strains. The assay does not require the purification of total DNA from the urine sample. Heating the sample for five minutes at 90°C is enough to release a sufficient amount of the amplification target to determine whether the pathogen is present. Urine contains polymerase chain reaction (PCR) inhibitors, but up to 5 μl of urine can be added without affecting sensitivity of the RPA, whereas the addition of 10 μl affects amplification efficiency significantly.

The C. trachomatis assay developed here was able to detect at least 50 copies of the CDS2 target. C. trachomatis harbors, on average, between four and ten copies of the plasmid per elementary body depending on the strain and development stage. The lowest detectable amount of the C. trachomatis RPA assay can therefore be translated to 5 to 12 pathogens per reaction and is in the same range as other nucleic acid amplification-based techniques.

The assay was tested on urine samples from 70 patients (51 females and 19 males) attending a sexual health clinic in Estonia. The samples were tested in parallel using RPA and Roche Cobas Amplicor C. trachomatis assays.

Fifty-eight samples tested negative in both assays. As no false negatives were detected, the clinical specificity of the C. trachomatis RPA assay can be estimated at 100%.

Twelve of the samples tested as positive using the Roche assay. Of these, 10 tested positive and two tested negative in the RPA reaction. Based on these results, the clinical sensitivity of the RPA assay can be estimated at 83%.

Of the 12 patients who tested positive, three complained of symptoms. The other nine patients were asymptomatic. Of the 58 C. trachomatis-negative patients, 15 (26%) complained of symptoms that could be associated with C. trachomatis infection. One of these tested positive for N. gonorrhoeae and M. genitalium. Others were diagnosed with bladder inflammation (two patients), bacterial vaginosis (five patients), yeast infection (four patients), or abdominal pain of non-gynecological origins (three patients).

Explore further: M. genitalium ups risk of pelvic inflammatory disease, cervicitis

More information: "Sensitive and rapid detection of Chlamydia trachomatis by recombinase polymerase amplification directly from urine samples," by Katrin Krõlov, Jekaterina Frolova, Oana Tudoran, Julia Suhorutsenko, Taavi Lehto, Hiljar Sibul, Imre Mäger, Made Laanpere, Indrek Tulp, and Ülo Langel, DOI: dx.doi.org/10.1016/j.jmoldx.2013.08.003. The Journal of Molecular Diagnostics, Volume 16, Issue 1 (January 2014)

Related Stories

M. genitalium ups risk of pelvic inflammatory disease, cervicitis

May 31, 2012
(HealthDay) -- Infection with Mycoplasma genitalium (M. genitalium) is an independent and strong risk factor for both cervicitis and pelvic inflammatory disease (PID), according to a study published in the June issue of the ...

New Chlamydia test shows type of infection

May 24, 2011
A new Chlamydia test can quickly and easily demonstrate the subtype (serovar) of the bacterium Chlamydia trachomatis a person is infected with. This has important clinical implications, because some Chlamydia subtypes, that ...

New highly efficient molecular probe for real-time PCR monitoring and genetic testing

August 7, 2013
Eprobe, a highly efficient and reliable fluorescent probe for PCR DNA amplification techniques and DNA analysis in hybridization experiments, has been developed by researchers from RIKEN and Japanese firm K.K.DNAFORM. This ...

Recommended for you

Building better tiny kidneys to test drugs and help people avoid dialysis

February 16, 2018
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.

Expanding Hepatitis C testing to all adults is cost-effective and improves outcomes

February 16, 2018
According to a new study, screening all adults for hepatitis C (HCV) is a cost-effective way to improve clinical outcomes of HCV and identify more infected people compared to current recommendations. Using a simulation model, ...

Study suggests expanded range for emerging tick-borne disease

February 16, 2018
Human cases of Borrelia miyamotoi, a tick-borne infection with some similarities to Lyme disease, were discovered in the eastern United States less than a decade ago. Now new research led by the Yale School of Public Health ...

Flu shot only 36 percent effective, making bad year worse (Update)

February 15, 2018
The flu vaccine is doing a poor job protecting older Americans and others against the bug that's causing most illnesses.

IFN-mediated immunity to influenza A virus infection influenced by RIPK3 protein

February 15, 2018
Each year, influenza kills half a million people globally with the elderly and very young most often the victims. In fact, the Centers for Disease Control and Prevention reported 37 children have died in the United States ...

A new class of drug to treat herpes simplex virus-1 infection

February 14, 2018
For patients with the herpes simplex-1 virus (HSV-1), there are just a handful of drugs available to treat the painful condition that can affect the eyes, mouth and genitals.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.